Skip to NavigationSkip to content

fallopian tube cancer

Clovis Oncology's Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the drug will now be made available immediately via the Cancer Drugs Fund (CDF) for women in England with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy.

The UK watchdog originally turned down the therapy due to concerns over the certainty of the data submitted, as well as over cost-effectiveness, based on the price put forward by Clovis.

NICE recommends AstraZeneca’s Lynparza after price reduction

Lynparza is the first cancer drug targeted to an inherited genetic fault to be available on the NHS

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer.

In draft guidance the UK healthcare watchdog recommends Lynparza (olaparib) for cancers in people who have tested positive for the BRCA1 or BRCA2 mutations, whose disease has responded to platinum-based chemotherapy. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches